The persistence of ZIST gradient abnormalities in psoriasis despite IL-23 blockade nominates this regulatory mechanism as an intriguing, complementary therapeutic target in overactivity of the Th17/Tc17 axis, as does recent work indicating that fibroblasts may also suppress psoriatic inflammation through ZFP36L2.47 This evidence concerns the gene ZFP36L2 and psoriasis.